ARCHIVES

ODAC Rejects Amsacrine NDA, Renews Idarubicin

This article is from The Cancer Letter archive.

Vol. 16 No. 35 | September 14, 1990

Download PDF Visit The Full Archive

Related Articles

In Brief: Calabresi Named To President’s Cancer Panel; Mays Leaves NCI Technology Office For IVAX

May 5, 1995

Olaparib Study Demonstrates No Changes In Overall Survival

March 30, 2012

Includes May issue of Business & Regulatory Report.

May 31, 2002

NCI Research Plan Proposes Spending $5 Billion In FY2002.

November 3, 2000

President to Propose 2 Percent Increase in NIH Budge, Slowing Funding Growth

January 15, 1999

In Brief: Diane Fink Moves to ACS California Div.; Preisler Names Director Of Cancer Center In Cincinnati

February 10, 1989